Whales Bet Big on Sarepta's Gene Therapy Gamble

Sarepta Therapeutics (SRPT) Options Activity Reveals Whales' Bullish Bet

A recent surge in options trading activity at Sarepta Therapeutics (SRPT) has caught the attention of market observers, with whale investors placing a significant bet on the biotech company's future performance. According to data from Benzinga Pro, a whopping 17,500 calls and just 2,500 puts were traded on SRPT options in the past week, indicating a strong bullish bias among large traders.

The majority of the trading activity occurred in the April 2025 options, with the majority of the calls being bought for $40 strike price. This suggests that whales are expecting SRPT's stock price to continue its upward trajectory, potentially reaching or exceeding the $40 mark by expiration.

Sarepta Therapeutics has been a hot topic in recent months, with its flagship product, Exondys 51, gaining FDA approval for the treatment of Duchenne muscular dystrophy. The company's pipeline is also filled with promising candidates, including gene therapies for various rare diseases.

Whales, known for their market-moving trades, have been increasingly active in the biotech space, with many targeting companies with strong growth potential and promising pipelines. In the case of SRPT, the whales' bet on the company's future performance may be driven by expectations of continued growth and expansion into new therapeutic areas.

While there is no guarantee that SRPT's stock price will reach the $40 mark, the sheer volume of call buying activity suggests that whales are confident in the company's ability to deliver strong returns. As always, investors should carefully consider their own risk tolerance and investment goals before making any trading decisions.